ONCS
Precisamente hay un artículo en SA de ayer que no está mal. Pego las partes referentes a la dilución:
After presenting positive Phase 2 Melanoma interim data at ASCO this past June, the stock price saw a quick boost followed by the announcement of a 10% dilution leading to uncertainty, and retail investor selloff. The price decline though drastic is not alarming as turbulent price activity is common in an OTC "penny" stock. Between the dilution and an expected several month wait for additional news to be released, the price will likely continue to drop till the next news event is announced.
With a market cap just barely over $100m, OncoSec has a large number of shares for a small company, 244m outstanding shares and another 15m shares authorized under a 2011 incentive plan. In addition, 29m shares are reserved for the issuance of outstanding warrants. Dilution has dragged the share price down from recent highs. The most recent S-3 filed early this year was for up to $75m of common stock, which at today's price would be another 120 million shares (a recent offering mentioned in the annual share holder letter closed on June 6th). OncoSec through their Articles of Incorporation are authorized to issue 3.2 billion shares of common stock. Like all Biotechnology companies which lack a source of revenue, additional dilution is always a risk factor which needs to be considered.
Current financial statements show the company is well funded for at least a year, if not longer. I believe this makes the risk of dilution within that time frame minimal, and with the achievement of milestones the share price should improve significantly as well. Company officials have stated they are funded sufficiently to complete a Phase 2B Melanoma trial slated to start this year. However, I believe at the current rate of expansion OncoSec may see another dilution if an expected partnership does not happen prior to the start of that trial.
http://seekingalpha.com/article/2384855-oncosec-medical-multiplying-immune-response
«Después de nada, o después de todo/ supe que todo no era más que nada.»